Femasys Stock (NASDAQ:FEMY)


RevenueOwnershipFinancialsChart

Previous Close

$1.12

52W Range

$0.25 - $4.75

50D Avg

$1.09

200D Avg

$1.20

Market Cap

$24.90M

Avg Vol (3M)

$175.37K

Beta

-2.81

Div Yield

-

FEMY Company Profile


Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Show More

Industry

Medical - Instruments & Supplies

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

32

IPO Date

Jun 18, 2021

Website

FEMY Performance


FEMY Financial Summary


Dec 23Dec 22Dec 21
Revenue$1.45M$1.21M$1.18M
Operating Income$-14.51M$-11.60M$-8.34M
Net Income$-14.25M$-11.39M$-7.54M
EBITDA$-13.92M$-10.81M$-6.92M
Basic EPS$-0.93$-1.26$-1.12
Diluted EPS$-0.93$-1.26$-1.12

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
NEPHNephros, Inc.
KRMDKORU Medical Systems, Inc.
POCIPrecision Optics Corporation, Inc.
UTMDUtah Medical Products, Inc.
PDEXPro-Dex, Inc.